Interestingly, none of the IBD patients with severe COVID-19 were on biologicals when in fact a substantial proportion of IBD patients in our population currently use biologicals, in particular anti-tumour necrosis factor (TNF) agents such as infliximab and adalimumab. Here, TNF is linked to COVID-19.